RE: Exclusivity or multiple deals?29 Apr 2026 10:55
LT,
'Is EMA ODD, FDA ODD and a 1mln fund raise in zero time "nothing tangible"? are RNSs discussing openly about pharma partners (potential), additional data needed, money spent on such studies, and the potential of a deal prior to any studies being concluded a figment of Dan's imangination?'
The ODD application work was justified on the back of statements saying that EMA was critical for getting a deal. That was back in 2023. We are now in 2026, a year after EMA ODD was granted and there is not even tangible evidence of an interested partner yet.
Just so you know, 'tangible' means something that can be touched, something seen to be real...not something we are constantly told but never see.
So no, it is not tangible. The current bid is .16p. There has been absolutely no benefit to investors at this point in time